ARTICLE | Company News
LigoCyte Pharmaceuticals, Takeda deal
April 15, 2013 7:00 AM UTC
Takeda will acquire LigoCyte for $60 million up front, plus potential milestones. LigoCyte's lead product is a norovirus VLP intranasal vaccine in Phase I/II testing to prevent norovirus gastroenterit...